Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress

What Was Tested

Researchers studied Angiotensin II in this randomized controlled trial publication.

To elucidate the effect of the angiotensin type 1 (AT1) receptor antagonist (AT1RA) eprosartan (E) on renal hemodynamics in normotensive and borderline hypertensive subjects, the researchers investigated the hormonal and renal hemodynamic responses during cardiopulmonary stress testing.

Who Took Part

By PubMed's age tags, the people studied were adults, men only.

In a prospective, double-blind, randomized, placebo-controlled crossover study, the effects of E on renal plasma flow (RPF), renal blood flow (RBF), glomerular filtration rate (GFR), and the concentration of angiotensin II (Ang II) levels were measured with the subjects at rest and during perturbation of cardiopulmonary baroreceptors using lower body negative pressure (LBNP).

The measurements were taken on day 7 of both intake phases.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Angiotensin II.

Some participants received a placebo instead of Angiotensin II, giving a reference point.

Each person switched between Angiotensin II and the comparison at some point, usually with a gap in between.

What Was Measured

To elucidate the effect of the angiotensin type 1 (AT1) receptor antagonist (AT1RA) eprosartan (E) on renal hemodynamics in normotensive and borderline hypertensive subjects, the researchers investigated the hormonal and renal hemodynamic responses during cardiopulmonary stress testing.

Topics PubMed links to this paper include Acrylates, Angiotensin II, Angiotensin Receptor Antagonists, Blood Pressure, Endocrine Glands, Glomerular Filtration Rate and Hemodynamics.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2003 (Kidney international), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.